Venus Remedies Statistics

Total Valuation

Venus Remedies has a market cap or net worth of INR 6.08 billion. The enterprise value is 4.46 billion.

Market Cap	6.08B
Enterprise Value	4.46B

Important Dates

The next estimated earnings date is Monday, August 4, 2025.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	13.37M
Shares Outstanding	n/a
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	-4.11%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	6.79M

Valuation Ratios

The trailing PE ratio is 13.42.

PE Ratio	13.42
Forward PE	n/a
PS Ratio	0.94
PB Ratio	1.08
P/TBV Ratio	1.33
P/FCF Ratio	7.92
P/OCF Ratio	7.03
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.01, with an EV/FCF ratio of 5.80.

EV / Earnings	9.83
EV / Sales	0.69
EV / EBITDA	7.01
EV / EBIT	10.86
EV / FCF	5.80

Financial Position

The company has a current ratio of 3.27, with a Debt / Equity ratio of 0.00.

Current Ratio	3.27
Quick Ratio	2.08
Debt / Equity	0.00
Debt / EBITDA	0.03
Debt / FCF	0.02
Interest Coverage	586.14

Financial Efficiency

Return on equity (ROE) is 8.64% and return on invested capital (ROIC) is 4.70%.

Return on Equity (ROE)	8.64%
Return on Assets (ROA)	3.82%
Return on Invested Capital (ROIC)	4.70%
Return on Capital Employed (ROCE)	7.11%
Revenue Per Employee	5.46M
Profits Per Employee	381,803
Employee Count	1,187
Asset Turnover	0.97
Inventory Turnover	3.41

Taxes

In the past 12 months, Venus Remedies has paid 265.10 million in taxes.

Income Tax	265.10M
Effective Tax Rate	36.91%

Stock Price Statistics

The stock price has increased by +25.23% in the last 52 weeks. The beta is 0.62, so Venus Remedies's price volatility has been lower than the market average.

Beta (5Y)	0.62
52-Week Price Change	+25.23%
50-Day Moving Average	379.12
200-Day Moving Average	331.41
Relative Strength Index (RSI)	66.27
Average Volume (20 Days)	66,306

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Venus Remedies had revenue of INR 6.48 billion and earned 453.20 million in profits. Earnings per share was 33.90.

Revenue	6.48B
Gross Profit	2.69B
Operating Income	410.30M
Pretax Income	718.30M
Net Income	453.20M
EBITDA	635.40M
EBIT	410.30M
Earnings Per Share (EPS)	33.90

Full Income Statement

Balance Sheet

The company has 1.64 billion in cash and 16.90 million in debt, giving a net cash position of 1.62 billion.

Cash & Cash Equivalents	1.64B
Total Debt	16.90M
Net Cash	1.62B
Net Cash Per Share	n/a
Equity (Book Value)	5.61B
Book Value Per Share	419.64
Working Capital	3.13B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 864.50 million and capital expenditures -96.30 million, giving a free cash flow of 768.20 million.

Operating Cash Flow	864.50M
Capital Expenditures	-96.30M
Free Cash Flow	768.20M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 41.56%, with operating and profit margins of 6.33% and 7.00%.

Gross Margin	41.56%
Operating Margin	6.33%
Pretax Margin	11.09%
Profit Margin	7.00%
EBITDA Margin	9.81%
EBIT Margin	6.33%
FCF Margin	11.86%

Dividends & Yields

Venus Remedies does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.01%
Shareholder Yield	n/a
Earnings Yield	7.45%
FCF Yield	12.63%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	5